In addition, the effect of docetaxel and thalidomide therapy on cell viability was the same as the effect of docetaxel plus VCAN siRNA, suggesting that targeting VCAN could be a potential therapeutic strategy in docetaxel-resistant PCa [64]. Here, VCAN is linked to posterior cortical atrophy.